Skip to main content

Table 2 Primary efficacy outcomes, Uganda therapeutic efficacy monitoring, 2018–2019

From: Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda

Outcome Kwania district Arua district Busia district
AL (28 days) DP (28 days) DP (42 days) AL (28 days) DP (28 days) DP (42 days) AL (28 days) DP (28 days) DP (42 days)
ETF n (%) 0 (0.0) 0 (0,0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
LCF n (%) 5 (4.8) 1 (1.0) 2 (2.1) 11 (11.1) 0 (0.0) 0 (0.0) 13 (12.7) 2 (2.1) 4 (4.2)
LPF n (%) 25 (24.0) 1 (1.0) 10 (10.5) 28 (28.3) 3 (3.1) 20 (20.8) 47 (46.1) 2 (2.1) 21 (22.3)
ACPR n (%) 74 (71.2) 93 (97.9) 83 (87.4) 60 (60.6) 93 (96.9) 76 (79.2) 42 (41.2) 91 (95.8) 69 (73.4)
Reinfectiona n (%) 25 (83.3) 2 (100) 10 (83.3) 32 (82.1) 3 (100) 15 (75.0) 50 (83.3) 3 (75.0) 18 (72.0)
Recrudescenceb n (%) 5 (16.7) 0 (0.0) 2 (16.7) 7 (17.9) 0 (0.0) 5 (25.0) 10 (16.7) 1 (25.0) 7 (28.0)
Uncorrected Kaplan Meier % [95% CI] 71.2 [63, 80] 97.9 [95, 100] 87.4 [81, 94] 60.6 [52, 71] 96.9 [94, 100] 79.2 [71, 88] 41.2 [33, 52] 95.8 [92, 100] 73.5 [65, 83]
Corrected Kaplan Meier % [95% CI] 94.4 [90, 99] 99.5 [99, 100] 97.5 [95, 100] 92.1 [86, 98] 100.0 [100, 100] 94.4 [90, 99] 87.2 [79, 95] 98.9 [97, 100] 92.1 [87, 98]
Uncorrected per protocol efficacy % [95% CI] 71.2 [61, 80] 97.9 [91, 100] 87.4 [79, 93] 60.6 [50, 70] 96.9 [88, 98] 79.2 [70, 87] 41.2 [32, 51] 95.8 [90, 99] 73.4 [63, 82]
Corrected per protocol efficacy % [95% CI] 93.1 [85, 98] 99.5 [95, 100] 97.3 [91, 100] 89.7 [80, 96] 100.0 [96, 100] 93.7 [86, 98] 80.1 [67, 90] 98.9 [94, 100] 90.8 [82, 96]
  1. ETF, early treatment failure; LCF, late clinical failure; LPF, late parasitological failure, ACPR, adequate clinical and parasitological response; AL, artemether-lumefantrine; DP, dihydroartemisinin-piperaquine
  2. aFor tabulation, reinfection defined as a recurrent infection with a posterior probability of recrudescence of < 50%
  3. bFor tabulation, recrudescence defined as a recurrent infection with a posterior probability of recrudescence of ≥ 50%